A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer Article

cited authors

  • Holloway, Robert W.; Thaker, Premal; Mendivil, Alberto A.; Ahmad, Sarfraz; Al-Niaimi, Ahmed N.; Barter, James; Beck, Tiffany; Chambers, Setsuko K.; Coleman, Robert L.; Crafton, Sarah M.; Crane, Erin; Ramez, Eskander; Ghamande, Sharad; Graybill, Whitney; Herzog, Thomas; Indermaur, Megan Dr; John, Veena S.; Landrum, Lisa; Lim, Peter C.; Lucci, Joseph A.; McHale, Michael; Monk, Bradley J.; Moore, Kathleen Nadine; Morris, Robert; O'Malley, David M.; Reid, Thomas J.; Richardson, Debra; Rose, Peter G.; Scalici, Jennifer M.; Silasi, Dan-Arin; Tewari, Krishnansu; Wang, Edward W.

authors

Publication Date

  • September 1, 2023

webpage

published in

category

keywords

  • Carcinoma, Ovarian Epithelial
  • Gynecology
  • Ovarian Cancer
  • Surgical Oncology

start page

  • 1458

end page

  • 1463

volume

  • 33

issue

  • 9